Get startedLog in
    Picture of Sun Pharma Advanced Research logo

    SPARC — Sun Pharma Advanced Research Income Statement

    0.000.00%
    in flag iconLast trade - 00:00
    HealthcareSpeculativeMid CapMomentum Trap
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual income statement for Sun Pharma Advanced Research, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

    2022
    March 31st
    2023
    March 31st
    2024
    March 31st
    2025
    March 31st
    2026
    March 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:ARSARSARSARSARS
    Standards:
    IAS
    IAS
    IAS
    IAS
    IAS
    Status:FinalFinalFinalFinalFinal
    Revenue
    Total Revenue1,3722,388755718391
    Cost of Revenue
    Gross Profit-18.8550-664-445-185
    Selling / General / Administrative Expenses
    Depreciation and Amortization
    Unusual Expense / Income
    Other Operating Expenses
    Total Operating Expenses3,3334,6244,8704,0582,926
    Operating Profit-1,961-2,236-4,115-3,341-2,535
    Total Net Non Operating Interest Income / Expense
    Gain / Loss on Sale of Assets
    Total Net Non Operating Interest Income / Expense
    Other Net Non Operating Costs
    Net Income Before Taxes-2,034-2,226-3,868-3,42815,530
    Provision for Income Taxes
    Net Income After Taxes-2,034-2,226-3,872-3,42515,532
    Net Income Before Extraordinary Items
    Net Income-2,034-2,226-3,872-3,42515,532
    Income Available to Common Shareholders Excluding Extraordinary Items
    Income Available to Common Shareholders Including Extraordinary Items
    Diluted Net Income-2,034-2,226-3,872-3,42515,532
    Diluted Weighted Average Shares
    Basic EPS Including Extraordinary Items
    Diluted EPS Including Extraordinary Items
    Diluted EPS Excluding Extraordinary Items
    Normalised Income Before Taxes
    Normalised Income After Taxes
    Normalised Income Available to Common Shareholders
    Diluted Normalised EPS-7.92-7.81-11.9-10.648.1